# A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer

> **NCT05354700** · PHASE2 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 20 (estimated)

## Conditions studied

- Small-cell Lung Cancer

## Interventions

- **DRUG:** HLX07
- **DRUG:** HLX10
- **DRUG:** carboplatin and etoposide

## Key facts

- **NCT ID:** NCT05354700
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-29
- **Primary completion:** 2024-03-29
- **Final completion:** 2024-05-29
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05354700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05354700, "A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05354700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*